Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript Summary
Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript Summary
Net loss was $3.7 million in Q3 2024, showing a 15% improvement from the previous quarter.The following is a summary of the Avinger, Inc. (AVGR) Q3 2024 Earnings Call Transcript:
以下是愛文思控股公司（AVGR）2024年第三季度業績會討論摘要：
Financial Performance:
財務表現:
Total revenue for Q3 2024 was $1.7 million, a slight decrease from previous figures.
Gross margin improved to 26% in Q3 2024 from 20% in the prior quarter, reflecting increased operating efficiency.
Net loss was $3.7 million in Q3 2024, showing a 15% improvement from the previous quarter.
2024年第三季度的總營業收入爲170萬美元，略有下降。
2024年第三季度的毛利率從上一季度的20%提高到26%，反映出運營效率提高。
2024年第三季度淨虧損爲370萬美元，較上一季度改善了15%。
Business Progress:
業務進展：
Implemented a cost savings program reducing overall headcount by 24%, including a one-third reduction in the commercial team, enhancing operating efficiency.
Expanded the Pantheris LV large vessel peripheral atherectomy catheter to full commercial launch, paired with the Lightbox 3 imaging console.
Advanced the development of a coronary CTO crossing system with the completion of Phase III trials and preparation for an FDA investigational device exemption application.
實施了一項成本節約計劃，全面減少了24%的總人員配備，包括商業團隊的三分之一減少，提高了運營效率。
將Pantheris LV大型血管周圍動脈切割導管全面商業化推出，配合Lightbox 3成像控制檯。
完成了第三期試驗，準備提交FDA調查設備豁免申請，推進冠脈CTO穿越系統的開發。
Opportunities:
機會：
The partnership with Zylox-Tonbridge opens up the large Chinese market for Avinger's devices and facilitates cost-effective manufacturing, with regulatory clearance anticipated in 2025.
Opportunities for substantial cost savings for hospitals using Avinger's products, potentially allowing for more efficient resource allocation.
與Zylox-Tonbridge的合作爲Avinger的設備開拓了龐大的中國市場，促進了成本效益的製造，預計將在2025年獲得監管審批。
使用Avinger產品的醫院有機會實現可觀的成本節約，可能有助於更有效地分配資源。
Risks:
風險：
No explicit risks/opportunities detected.
未檢測到明確的風險/機會。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
